🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Utter shame...!!! Let's go all out this time... No one should be spared!

It should read “No proven CV neutrality like Lina and Sitagliptin”

*कब तक बोझ संभाला जाए* *द्वंद्व कहां तक पाला जाए* *दूध छीन बच्चों के मुख से* *क्यों नागों को पाला जाए* *दोनों ओर लिखा हो भारत* *सिक्का वही उछाला जाए* *तू भी है राणा का वंशज* *फेंक जहां तक भाला जाए* *इस बिगड़ैल पड़ोसी को तो* *फिर शीशे में ढाला जाए!* #MaharanaPratapJayanti May’9

Escalate…Escalate PM Modi ji. Never believe on them. Look at their record..you know better than all of us! Narendra Modi 🙏🏽

Pl don’t stop and finish remaining 12 of 21 terrorist camp before drinking a cup of tea tomorrow morning… word “ceasefire” is a fake terminology with the neighbours!!!

You are the best journalist India could have. Thank you for updating us on entire issue in most precise way. Way to go…Shiv Aroor

DAPA-HF & EMPEROR-Reduced trials reveal significant absolute risk reductions in cardiovascular, renal, & mortality outcomes with dapagliflozin and empagliflozin. SGLT2 inhibitors continue to redefine heart failure and CKD management. tandfonline.com/doi/full/10.10…

Thank you 🙏🏽💐

Have SGLT-2 inhibitors DELIVERed an EMPhatic win in heart failure and chronic kidney disease? tandfonline.com/doi/full/10.10…

DAPA-CKD & EMPA-KIDNEY trials highlight significant absolute risk reductions in renal, cardiovascular, & mortality outcomes with dapagliflozin and empagliflozin. SGLT2 inhibitors continue to transform CKD care across diverse patient populations. tandfonline.com/doi/full/10.10…

Have SGLT-2 inhibitors DELIVERed an EMPhatic win in heart failure and chronic kidney disease? SGLT-2i in people CKD showing consistent reduction in the primary outcome of renal composite in both diabetic and non-diabetic kidney diseases tandfonline.com/doi/full/10.10…

Thank you for reading and highlighting our manuscript..💐 hope you all liked it 🙏🏽

Revisiting Diabetes Classification — Insights, Challenges & Indian Relevance of the ANDIS Framework Dr. A. K. Singh; MD, DM (Endo) 🇮🇳 Endocrine Society of India RSSDI (official) Dr. Shashank Joshi Dr Ambrish Mithal anoop misra Eric Topol Prof Kamlesh Khunti Scott Isaacs Samuel Hume Dr sthanu subramanian 🧑‍⚕️ Authors: Dr. Akriti

Dr. Pramod Sawant The minister has to be fired.. there is no other way..

Everyone (including the doctor who prescribed Inj B12 for sciatica 🤦🏻‍♂️) should know that Inj B12 is not an emergency drug and neither superior to oral B12 (indeed few studies found oral better than Inj B12) except those who have pernicious anemia, had GI surgeries or malabsorption

Our New Editorial...Prof Kamlesh Khunti Dr Ambrish Mithal anoop misra Dr. Shashank Joshi Dr.V.Mohan Dr Amar Puttanna 🎸 Unnikrishnan AG Tirzepatide: Responders vs. Non-Responders | Singh | Clinical Diabetology journals.viamedica.pl/clinical_diabe…

Such RWS have many confounding biases. No such increase was noted in RCTs including SURMOUNT-2 for 72 weeks despite an HbA1c reduction (placebo-subtracted) of -1.6%!

Other recently published cohort study in JAMA showed increased AMD with GLP-1RA. jamanetwork.com/journals/jamao… Whom to believe? Are these observational studies believable? Apart from FOCUS any such studies in progress? Dr Ambrish Mithal anoop misra

Epic..😂😂🤛🏻🤛🏻